Multiple Myeloma, Phase I-II
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Alexis Walker
- Alfredo Axtmayer
- Alison Johnson
- Anca Bulgaru, MD
- Andrea Brennan
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- Catherine Wei, MD
- D. Barry Boyd, MD, MS
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Elizabeth Cappiello
- Emily Kopas, APRN, OCN
- Erica Stevens
- Francesca Montanari, MD
- Gloria Huang, MD, FACOG
- Harold Tara Jr, MD
- Iris Isufi, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Karen Ann Hammond, DNP, APRN, ACNP (BC)
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Larisa Fleysher
- Leena Rahmat
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Renee Moye
- Robert Legare, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Thomen, APRN
- Stacey LaRosa
- Stephen Lattanzi, MD
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Victor Chang, MD
- Vidya Kesavan
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000028918